Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 21 professional analysts, the 12-month price target for Regeneron Pharmaceuticals stock ranges from a low of $547 to a high of $1,175. The average analyst price target of $808.43 forecasts a 43.96% increase in the stock price over the next year.

Price Target: $808.43 (+43.96%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$547	$808.43	$804	$1,175
Change	-2.59%	+43.96%	+43.18%	+109.24%

Analyst Ratings

The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	7	6	7	7	6	5
Buy	12	12	11	11	11	10
Hold	5	4	4	4	4	5
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	25	23	23	23	22	21

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Srikripa Devarakonda Truist Securities	Truist Securities	Strong Buy Maintains $940 → $812	Strong Buy	Maintains	$940 → $812	+44.60%	Aug 11, 2025
Evan David Seigerman BMO Capital	BMO Capital	Buy Maintains $600 → $640	Buy	Maintains	$600 → $640	+13.97%	Aug 4, 2025
Matthew Harrison Morgan Stanley	Morgan Stanley	Buy Maintains $754 → $761	Buy	Maintains	$754 → $761	+35.52%	Aug 4, 2025
Brian Abrahams RBC Capital	RBC Capital	Hold Maintains $688 → $695	Hold	Maintains	$688 → $695	+23.76%	Aug 4, 2025
Yatin Suneja Guggenheim	Guggenheim	Strong Buy Maintains $810 → $815	Strong Buy	Maintains	$810 → $815	+45.13%	Aug 4, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

13.66B

Decreased by -3.84%

from 14.20B

Revenue Next Year

14.57B

Increased by 6.65%

from 13.66B

EPS This Year

36.10

Decreased by -5.85%

from 38.34

EPS Next Year

40.28

Increased by 11.59%

from 36.10

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	8.50B	16.07B	12.17B	13.12B	14.20B	13.66B	14.57B	16.12B
Revenue Growth	29.58%	89.14%	-24.26%	7.76%	8.27%	-3.84%	6.65%	10.67%
EPS	30.52	71.97	38.22	34.77	38.34	36.10	40.28	49.45
EPS Growth	65.33%	135.81%	-46.90%	-9.03%	10.27%	-5.85%	11.59%	22.75%
Forward PE	-	-	-	-	-	15.56	13.94	11.36
No. Analysts	-	-	-	-	-	30	28	22

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	14.9B	16.5B	18.0B
Avg	13.7B	14.6B	16.1B
Low	12.2B	12.6B	14.2B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	5.0%	20.5%	23.7%
Avg	-3.8%	6.6%	10.7%
Low	-14.2%	-7.5%	-2.2%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	44.47	56.21	66.61
Avg	36.10	40.28	49.45
Low	29.78	32.28	37.92

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	16.0%	55.7%	65.4%
Avg	-5.8%	11.6%	22.8%
Low	-22.3%	-10.6%	-5.9%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.